TDRD1 has been discovered to be a direct target of (ETS-related gene) ERG, which promotes tumor initiation and progression in TMPRSS2-ERG fusion prostate cancer and could be a new immunotherapy target (40–42). This evidence concerns the gene TMPRSS2 and prostate cancer.